These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
253 related articles for article (PubMed ID: 25800643)
1. Anti-type II collagen antibodies detection and avidity in patients with oligoarticular and polyarticular forms of juvenile idiopathic arthritis. Araujo GR; Fonseca JE; Fujimura PT; Cunha-Junior JP; Silva CH; Mourão AF; Canhão H; Goulart LR; Gonçalves J; Ueira-Vieira C Immunol Lett; 2015 May; 165(1):20-5. PubMed ID: 25800643 [TBL] [Abstract][Full Text] [Related]
2. A novel reactive epitope-based antigen targeted by serum autoantibodies in oligoarticular and polyarticular juvenile idiopathic arthritis and development of an electrochemical biosensor. Araujo GR; Fujimura PT; Vaz ER; Silva TA; Rodovalho VR; Britto-Madurro AG; Madurro JM; Fonseca JE; Silva CH; Santos PS; Mourão AF; Canhão H; Goulart LR; Gonçalves J; Ueira-Vieira C Immunobiology; 2016 May; 221(5):634-40. PubMed ID: 26806845 [TBL] [Abstract][Full Text] [Related]
3. Anti-type II collagen antibodies, anti-CCP, IgA RF and IgM RF are associated with joint damage, assessed eight years after onset of juvenile idiopathic arthritis (JIA). Berntson L; Nordal E; Fasth A; Aalto K; Herlin T; Nielsen S; Rygg M; Zak M; Rönnelid J; Pediatr Rheumatol Online J; 2014; 12():22. PubMed ID: 24944545 [TBL] [Abstract][Full Text] [Related]
4. The diagnostic value of anti-cyclic citrullinated peptide (CCP) antibodies in children with Juvenile Idiopathic Arthritis. Brunner J; Sitzmann FC Clin Exp Rheumatol; 2006; 24(4):449-51. PubMed ID: 16956438 [TBL] [Abstract][Full Text] [Related]
5. High Levels of DEK Autoantibodies in Sera of Patients With Polyarticular Juvenile Idiopathic Arthritis and With Early Disease Flares Following Cessation of Anti-Tumor Necrosis Factor Therapy. Mor-Vaknin N; Rivas M; Legendre M; Mohan S; Yuanfan Y; Mau T; Johnson A; Huang B; Zhao L; Kimura Y; Spalding SJ; Morris PW; Gottlieb BS; Onel K; Olson JC; Edelheit BS; Shishov M; Jung LK; Cassidy EA; Prahalad S; Passo MH; Beukelman T; Mehta J; Giannini EH; Adams BS; Lovell DJ; Markovitz DM Arthritis Rheumatol; 2018 Apr; 70(4):594-605. PubMed ID: 29287303 [TBL] [Abstract][Full Text] [Related]
6. Effect of age on prevalence of anticitrullinated protein/peptide antibodies in polyarticular juvenile idiopathic arthritis. Dewint P; Hoffman IE; Rogge S; Joos R; Union A; Dehoorne J; Delanghe J; Veys EM; De Keyser F; Elewaut D Rheumatology (Oxford); 2006 Feb; 45(2):204-8. PubMed ID: 16188943 [TBL] [Abstract][Full Text] [Related]
7. Anticyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. Brunner JK; Sitzmann FC Mod Rheumatol; 2006; 16(6):372-5. PubMed ID: 17164999 [TBL] [Abstract][Full Text] [Related]
9. Anti-endothelial cell antibodies are prevalent in juvenile idiopathic arthritis: implications for clinical disease course and pathogenesis. Bloom BJ; Toyoda M; Petrosian A; Jordan S Rheumatol Int; 2007 May; 27(7):655-60. PubMed ID: 17165085 [TBL] [Abstract][Full Text] [Related]
10. Anti-α-1,4-D-polygalacturonic acid antibodies as a new biomarker for juvenile idiopathic arthritis. Huang J; Wu Z; Quan W; Ye X; Dai X; Luo J; Han X; Li X; Zheng W Clin Rheumatol; 2024 Sep; 43(9):2919-2926. PubMed ID: 38997543 [TBL] [Abstract][Full Text] [Related]
11. Juvenile idiopathic arthritis (JIA): a screening study to measure class II skeletal pattern, TMJ PDS and use of systemic corticosteroids. Mandall NA; Gray R; O'Brien KD; Baildam E; Macfarlane TV; Davidson J; Sills J; Foster H; Gardner-Medwin J; Garrahy A; Millett D; Mattick R; Walsh T; Ward S J Orthod; 2010 Mar; 37(1):6-15. PubMed ID: 20439922 [TBL] [Abstract][Full Text] [Related]
12. Determination of anti-cyclic citrullinated peptide antibodies in the sera of patients with juvenile idiopathic arthritis. Low JM; Chauhan AK; Kietz DA; Daud U; Pepmueller PH; Moore TL J Rheumatol; 2004 Sep; 31(9):1829-33. PubMed ID: 15338508 [TBL] [Abstract][Full Text] [Related]
13. Serologic Evidence of Gut-driven Systemic Inflammation in Juvenile Idiopathic Arthritis. Fotis L; Shaikh N; Baszis KW; Samson CM; Lev-Tzion R; French AR; Tarr PI J Rheumatol; 2017 Nov; 44(11):1624-1631. PubMed ID: 28916545 [TBL] [Abstract][Full Text] [Related]
14. Anti-cyclic citrullinated peptide (anti-CCP) antibody in juvenile idiopathic arthritis (JIA): correlations with disease activity and severity of joint damage (a multicenter trial). Omar A; Abo-Elyoun I; Hussein H; Nabih M; Atwa H; Gad S; Emad Y Joint Bone Spine; 2013 Jan; 80(1):38-43. PubMed ID: 22575064 [TBL] [Abstract][Full Text] [Related]
15. Anticitrullinated protein antibodies and radiological progression in juvenile idiopathic arthritis. Lipinska J; Brózik H; Stanczyk J; Smolewska E J Rheumatol; 2012 May; 39(5):1078-87. PubMed ID: 22382337 [TBL] [Abstract][Full Text] [Related]
20. Anti-cyclic citrullinated peptide (anti-CCP) antibodies in children with juvenile idiopathic arthritis. van Rossum M; van Soesbergen R; de Kort S; ten Cate R; Zwinderman AH; de Jong B; Dijkmans B; van Venrooij WJ J Rheumatol; 2003 Apr; 30(4):825-8. PubMed ID: 12672206 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]